Insilico Medicine Achieves Industry First Nominating Preclinical Candidate Discovered by AI
Insilico Medicine Achieves Industry First Nominating Preclinical Candidate for Idiopathic Pulmonary Fibrosis With Both Novel Drug Target and Novel Molecule Discovered by Artificial Intelligence
HONG KONG, Feb. 24, 2021 /PRNewswire/ Insilico Medicine has demonstrated a breakthrough in Artificial Intelligence ( AI ) and drug discovery - linking together generative chemistry and biology for the first time - to discover a novel preclinical candidate addressing idiopathic pulmonary fibrosis
( IPF ) and be validated with multiple human cell and animal model experiments. Often found implicated in a wide range of diseases and multiple organs such as lung, liver and kidney, IPF addresses a very broad medical need that affects hundreds of thousands of individuals worldwide.